Anilinoquinazolines as protein tyrosine kinase inhibitors
US6933299B1 · kind B1 · utility
6Cited by
15References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2000 |
| Grant date | Aug 23, 2005 |
| Priority date | — |
| Expiry date | Jan 2, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.